How much does Mogamulizumab cost?

Mogamulizumab is an immunotherapy drug that is widely used to treat a malignant tumor called T cell lymphoma (T-cell lymphoma). It is a monoclonal antibody that specifically targets the CCR4 receptor on the surface of CD4+ T cells, a chemokine receptor that is often overexpressed in T cell lymphoma. The unique mechanism of moglizumab makes it a promising drug option for the treatment of TT cell lymphoma.

Moglizumab works in several ways. First, it can directly recognize and bind to the CCR4 receptor, causing the signaling pathway inside the receptor to be blocked, reducing the proliferation and viability of malignant T cells. Secondly, moglizumab can also enhance the anti-tumor effect by activating the body's immune system. It can prompt natural killer cells (NK cells) and other immune cells to recognize and attack malignant T cells, increasing the immune system's attack on tumors.

Moglizumab has been approved to treat two types of T cell lymphoma: peripheral T-cell lymphoma (Peripheral T-cell lymphoma, PTCL) and skin T cell lymphoma (Cutaneous T-cell lymphoma, CTCL). These diseases are often difficult to treat, but moglizumab offers patients a new treatment option.

However, moglizumab may also cause some adverse reactions, including skin reactions, infections, nausea, fatigue, etc. Therefore, before using moglizumab, doctors will evaluate the patient's overall health and weigh the potential risks of treatment against the benefits.

MoglizumabIt is already on the market in China, but it is not covered by medical insurance. Please consult your local hospital pharmacy for specific prices.